Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other financing activities (2021 - 2025)

InMed Pharmaceuticals' Other financing activities history spans 5 years, with the latest figure at $137178.0 for Q3 2025.

  • For Q3 2025, Other financing activities fell 28.49% year-over-year to $137178.0; the TTM value through Dec 2025 reached $386634.0, up 40.77%, while the annual FY2025 figure was $883978.0, 57.25% up from the prior year.
  • Other financing activities reached $137178.0 in Q3 2025 per INM's latest filing, up from $57632.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.1 million in Q4 2022 to a low of $25191.0 in Q3 2023.
  • Average Other financing activities over 5 years is $351639.8, with a median of $158148.0 recorded in 2021.
  • Peak YoY movement for Other financing activities: crashed 89.54% in 2022, then skyrocketed 661.48% in 2024.
  • A 5-year view of Other financing activities shows it stood at $179118.0 in 2021, then soared by 536.02% to $1.1 million in 2022, then plummeted by 97.79% to $25191.0 in 2023, then skyrocketed by 128.78% to $57632.0 in 2024, then soared by 138.02% to $137178.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Other financing activities are $137178.0 (Q3 2025), $57632.0 (Q4 2024), and $191824.0 (Q3 2024).